Roche reported two positive Phase 3 trials for its BTK inhibitor in multiple sclerosis, showing efficacy across relapsing disease and signals in primary progressive cohorts. The results mark a notable rebound for the BTK class after prior setbacks and set Roche up to pursue regulatory submissions in multiple MS indications. Analysts cautioned that regulators will scrutinize the chronic safety profile and whether the data package is robust enough for approval in progressive forms of MS.